Biotech · Public company · Lexington, MA, US
Keros Therapeutics, Inc.
Ticker KROS · SEC CIK 0001664710
Track this companyFree. Adds Keros Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline3
- Dose A KER-012Phase 2 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- Dose B KER-012Phase 2 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- Dose C KER-012Phase 2 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).PHASE2 · TERMINATED · started Oct 17, 2023ClinicalTrials.gov NCT05975905 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 25, 2026 · fetched Nov 12, 2026